New progress in diagnosis and treatment of lung cancer
10.13267/j.cnki.syzlzz.2025.046
- VernacularTitle:肺癌诊治新进展
- Author:
Zhenli LONG
1
;
Ying YANG
1
;
Yongfeng YU
1
;
Shun LU
1
Author Information
1. 上海交通大学医学院附属胸科医院,上海市肺部肿瘤临床医学中心,上海 200030
- Publication Type:Journal Article
- Keywords:
lung cancer;
multidisciplinary team;
immunotherapy;
targeted therapy
- From:
Practical Oncology Journal
2025;40(4):293-305
- CountryChina
- Language:Chinese
-
Abstract:
This review summarizes recent clinical progress in the field of lung cancer within the multidisciplinary team(MDT)diagnosis and treatment model across domestic and international studies.In the perioperative treatment of early-stage resectable non-small-cell lung cancer(NSCLC),the"sandwich"strategy combining preoperative neoadjuvant therapy with postoperative adjuvant therapy has demonstrat-ed significant survival benefits for patients.Notably,domestic toripalimab combined chemotherapy significantly increases the major patho-logic response(MPR)rate and event-free survival(EFS)rate of resectable stage Ⅲ NSCLC patients,emerging as a novel treatment regimen for perioperative NSCLC.For unresctable NSCLC patients,consolidative therapy combined with osimertinib,a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor,following radical chemotherapy has significantly extended progression free survival,filling the gap in targeted therapy for stage Ⅲ lung cancer.Furthermore,the combination of immunotherapy and anti-angiogenic agents has ef-fectively improved the overall survival of advanced NSCLC patients.Significant progress has also been made in the field of antibody-drug conjugates,with agents such as sacituzumab and trastuzumab demonstrating substantial therapeutic efficacy.In the field of extensive-stage small-cell lung cancer(ES-SCLC),the bispecific antibody tarlatamab targeting Delta-like ligand 3(DLL3)and cluster of differentiation 3(CD3)has exhibited significant efficacy,and has received accelerated approval from U.S.Food and Drug Administration(FDA)as a sec-ond-line treatment for ES-SCLC.
